A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2013
At a glance
- Drugs Decitabine (Primary)
- Indications Bladder cancer; Breast cancer; Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 Sep 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 22 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2006 Status change